AMY SCHEFLER to Treatment Outcome
This is a "connection" page, showing publications AMY SCHEFLER has written about Treatment Outcome.
Connection Strength
0.346
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.
Score: 0.070
-
Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes. Am J Ophthalmol. 2020 08; 216:165-173.
Score: 0.054
-
USE OF FEMORAL ARTERY ULTRASOUND DURING INTRAARTERIAL CHEMOTHERAPY FOR CHILDREN UNDER 10 KG WITH RETINOBLASTOMA. Retina. 2018 07; 38(7):1420-1426.
Score: 0.048
-
Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):e275-e282.
Score: 0.043
-
Advanced Coats' disease. Management with repetitive aggressive laser ablation therapy. Retina. 2008 Mar; 28(3 Suppl):S38-41.
Score: 0.023
-
Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007 Jan; 114(1):162-9.
Score: 0.021
-
MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
Score: 0.018
-
Re-treatment of locally recurrent uveal melanoma with repeat eye plaque I-125 brachytherapy: A single institution experience. Brachytherapy. 2024 Sep-Oct; 23(5):604-609.
Score: 0.018
-
Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology. 2004 May; 111(5):984-91.
Score: 0.018
-
Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Invest Ophthalmol Vis Sci. 2023 06 01; 64(7):35.
Score: 0.017
-
Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial. Graefes Arch Clin Exp Ophthalmol. 2022 Jan; 260(1):47-54.
Score: 0.015